HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DECIEM Analyzes Billions Of Google Searches To Tackle Cosmetic Ingredient ‘Misconceptions’

Executive Summary

The Estee Lauder Companies’ outfit breaks down the cosmetic safety assessment process, the science of skin inflammation and sensitivity, and safe and effective use of highly searched ingredients including zinc, hyaluronic acid and retinol in a September report aimed at bringing clarity to conversations online.

You may also be interested in...



ICCR-15: International Cosmetics Regulator Group Tackles Consumer Safety Perceptions

The International Cooperation on Cosmetics Regulations continues efforts to minimize barriers to international trade through regulatory convergence, while also taking steps to educate consumers on cosmetics safety issues that may be widely misunderstood. Personal Care Products Council leadership discusses developments from the regulator group’s 15th annual meeting in June.

J&J’s OGX Joins Brands Alleged To Cause Hair Loss In US Class Action Complaints

Formaldehyde donor DMDM hydantoin may be the ingredient in OGX hair-care products responsible for “hundreds if not thousands” of cases of hair loss and other injuries, plaintiff La Wanda Renee Key suggests in her 5 March class action complaint in California federal court.

Estee Lauder Companies To Make ‘Abnormal Beauty’ Its Own

The beauty titan will increase its stake in DECIEM to 76% in a deal valuating The Ordinary skin-care owner at $2.2bn. Remaining interests will be acquired after three years, according to the announcement.

Related Content

Topics

UsernamePublicRestriction

Register

RS151760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel